Salomon Manier

List of Publications by Year
in descending order

135 papers	4,752 citations	117625 34 h-index	106344 65 g-index
139 all docs	139 docs citations	139 times ranked	7190 citing authors

#	Article	IF	Citations
1	Current state and next-generation CAR-T cells in multiple myeloma. Blood Reviews, 2022, 54, 100929.	5.7	38
2	Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood, 2022, 139, 2747-2757.	1.4	16
3	Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood, 2021, 137, 2360-2372.	1.4	26
4	International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia, 2021, 35, 18-30.	7.2	69
5	Can palliative care consultation increase integration of palliative care for patients with hematologic malignancies?. Blood Advances, 2021, 5, 2123-2127.	5.2	4
6	Antibody-drug conjugate in multiple myeloma. Hematologie, 2021, 27, 26-34.	0.0	0
7	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. New England Journal of Medicine, 2021, 385, 46-58.	27.0	268
8	Effective anti-BCMA retreatment in multiple myeloma. Blood Advances, 2021, 5, 3016-3020.	5.2	30
9	Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. Blood, 2021, 138, 2746-2746.	1.4	3
10	Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5). Blood, 2021, 138, 1835-1835.	1.4	10
11	Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort. Blood, 2021, 138, 3764-3764.	1.4	2
12	Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma. Blood, 2021, 138, 330-330.	1.4	2
13	In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present from the Diagnosis in Tiny Undetectable Subclones. Blood, 2021, 138, 77-77.	1.4	2
14	Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. a Multicenter Phase 2 Study (IFM 2018-02) of the Intergroupe Francophone Du MyÃ©lome (IFM). Blood, 2021, 138, 83-83.	1.4	4
15	Modified Delphi Method Identifies Consensus Areas for Routine Minimal Residual Disease Testing in Multiple Myeloma. Blood, 2021, 138, 1631-1631.	1.4	0
16	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia, 2020, 34, 224-233.	7.2	122
17	On the road to molecular prognostication in SMM. Leukemia, 2020, 34, 331-332.	7.2	1
18	Daratumumab is effective in the relapsed or refractory systemic lightâ€chain amyloidosis but associated with high infection burden in a frail realâ€life population. British Journal of Haematology, 2020, 188, e24-e27.	2.5	26

#	Article	IF	Citations
19	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	12.8	98
20	Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy. Journal of Clinical Oncology, 2020, 38, 2647-2657.	1.6	24
21	Genome instability in multiple myeloma. Leukemia, 2020, 34, 2887-2897.	7.2	63
22	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 2020, 1, 493-506.	13.2	209
23	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	1.6	110
24	Antigen excess pitfall for free light chains measurements solved by ELISA assay. American Journal of Hematology, 2019, 94, E120-E122.	4.1	3
25	Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014â€04 (Etoile du Nord) trial. British Journal of Haematology, 2019, 187, 319-327.	2.5	18
26	Response to pneumococcal vaccination in multiple myeloma. Cancer Medicine, 2019, 8, 3822-3830.	2.8	20
27	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 332-344.	0.4	16
28	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances, 2019, 3, 995-1002.	5.2	15
29	Progression signature underlies clonal evolution and dissemination of Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e19-e20.	0.4	0
30	A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e40-e41.	0.4	4
31	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e27.	0.4	0
32	Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e5-e6.	0.4	1
33	In vivo modeling of clonal competition using CRISPR-based gene editing reveals novel fitness variables in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e110.	0.4	0
34	A High-Throughput Drug Screen Reveals a Novel Compound Class That Significantly Depletes IRF4 Expression in Multiple Myeloma. Blood, 2019, 134, 5545-5545.	1.4	1
35	Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03). Blood, 2019, 134, 3190-3190.	1.4	0
36	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. Blood, 2019, 134, 853-853.	1.4	0

#	Article	IF	Citations
37	Targeting MYC in multiple myeloma. Leukemia, 2018, 32, 1295-1306.	7.2	89
38	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics, 2018, 17, 1454-1463.	4.1	70
39	Platelets Enhance Multiple Myeloma Progression via IL-1Î² Upregulation. Clinical Cancer Research, 2018, 24, 2430-2439.	7.0	44
40	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood, 2018, 131, 301-310.	1.4	216
41	Pathology and Genetics of Multiple Myeloma. , 2018, , .		0
42	Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. Blood Advances, 2018, 2, 2811-2813.	5.2	69
43	Profiling of circulating exosomal miRNAs in patients with WaldenstrÃ¶m Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	2.5	17
44	A predictive model for risk of early gradeâ€‰â‰¥â€‰3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia, 2018, 32, 1404-1413.	7.2	53
45	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia, 2018, 32, 1739-1750.	7.2	34
46	Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in Oncology, 2018, 8, 665.	2.8	47
47	Blocking IFNAR1 inhibits multiple myelomaâ€“driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	8.2	80
48	Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 154-154.	1.4	19
49	Founding Precision Therapy in 1q-Amplified Multiple Myeloma. Blood, 2018, 132, 1007-1007.	1.4	12
50	Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France. Blood, 2018, 132, 5660-5660.	1.4	4
51	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. Blood, 2018, 132, 55-55.	1.4	0
52	In Vivo Modeling of Clonal Competition Using CRISPR-Based Gene Editing Reveals Novel Fitness Variables in Multiple Myeloma. Blood, 2018, 132, 57-57.	1.4	0
53	Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood, 2017, 129, 2429-2436.	1.4	214
54	A novel in vivo model for studying conditional dual loss of BLIMPâ€‘1 and p53 in Bâ€cells, leading to tumor transformation. American Journal of Hematology, 2017, 92, E138-E145.	4.1	3

#	Article	IF	Citations
55	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	12.4	53
56	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports, 2017, 19, 218-224.	6.4	92
57	Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. Leukemia, 2017, 31, 2426-2434.	7.2	72
58	Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Annals of Oncology, 2017, 28, 468-477.	1.2	62
59	Metformin Affects Cortical Bone Mass and Marrow Adiposity in Diet-Induced Obesity in Male Mice. Endocrinology, 2017, 158, 3369-3385.	2.8	54
60	The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia, 2017, 31, 853-860.	7.2	72
61	Genomic complexity of multiple myeloma and its clinical implications. Nature Reviews Clinical Oncology, 2017, 14, 100-113.	27.6	413
62	Role of IRF4 in resistance to immunomodulatory (IMid) compoundsÂ® in WaldenstrÃ¶mâ€™s macroglobulinemia. Oncotarget, 2017, 8, 112917-112927.	1.8	5
63	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e400-e406.	3.8	2
64	IgMÎº and IgMÎ» Measurements for the Assessment of Patients with WaldenstrÃ¶m's Macroglobulinaemia. Clinical Cancer Research, 2016, 22, 5152-5158.	7.0	9
65	Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. Current Opinion in Hematology, 2016, 23, 426-433.	2.5	33
66	Exome sequencing reveals recurrent germ line variants in patients with familial WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 127, 2598-2606.	1.4	22
67	Epigenetics in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 35-49.	0.5	7
68	Genomic Aberrations in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 23-34.	0.5	21
69	Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia, 2016, 30, 1103-1115.	7.2	46
70	Exosomes in Tumor Angiogenesis. Methods in Molecular Biology, 2016, 1464, 25-34.	0.9	32
71	Driver Mutation in Waldenstrom's Macroglobullinemia and Their Clonal Heterogeneity during Progression and Relapse. Blood, 2016, 128, 1092-1092.	1.4	2
72	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. Blood, 2016, 128, 1137-1137.	1.4	2

#	Article	IF	Citations
73	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. Blood, 2016, 128, 197-197.	1.4	8
74	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e400-e406.	3.8	4
75	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. Blood, 2016, 128, 237-237.	1.4	0
76	Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma. Blood, 2016, 128, 4483-4483.	1.4	0
77	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. Blood, 2016, 128, 4169-4169.	1.4	0
78	In Vivo Analysis of Clonal Evolution of Multiple Myeloma. Blood, 2016, 128, 799-799.	1.4	0
79	Profiling of Circulating Exosomes in Patients with WaldenstrÃ¶m Macroglobulinemia. Blood, 2016, 128, 2940-2940.	1.4	1
80	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	6.4	123
81	The cancer glycome: Carbohydrates as mediators of metastasis. Blood Reviews, 2015, 29, 269-279.	5.7	91
82	Targeting the bone marrow microenvironment in multiple myeloma. Immunological Reviews, 2015, 263, 160-172.	6.0	323
83	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. Blood, 2015, 126, 23-23.	1.4	37
84	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. Blood, 2015, 126, 502-502.	1.4	4
85	Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria?. Blood, 2015, 126, 3042-3042.	1.4	0
86	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. Blood, 2015, 126, 1755-1755.	1.4	0
87	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 2015, 126, 1770-1770.	1.4	4
88	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. Blood, 2015, 126, 1793-1793.	1.4	1
89	Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma. PLoS ONE, 2014, 9, e110973.	2.5	29
90	The Role of miRNAs in Plasma Cell Dyscrasias. MicroRNA (Shariqah, United Arab Emirates), 2014, 2, 165-173.	1.2	3

#	Article	IF	Citations
91	Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer Journal, 2014, 4, e204-e204.	6.2	11
92	IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer, 2014, 120, 3952-3957.	4.1	29
93	Targeting survival and cell trafficking in multiple myeloma and <scp>W</scp>aldenstrom macroglobulinemia using panâ€class <scp>I PI</scp>3<scp>K</scp> inhibitor, buparlisib. American Journal of Hematology, 2014, 89, 1030-1036.	4.1	14
94	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood, 2014, 124, 3250-3259.	1.4	109
95	Role of endothelial progenitor cells in cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 26-39.	7.4	70
96	Regulation of microRNAs in cancer metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 255-265.	7.4	132
97	Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10287-10292.	7.1	234
98	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood, 2014, 124, 1765-1776.	1.4	97
99	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	1.4	51
100	Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma. Blood, 2014, 124, 3370-3370.	1.4	1
101	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. Blood, 2014, 124, 3431-3431.	1.4	8
102	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. Blood, 2014, 124, 2051-2051.	1.4	1
103	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. Blood, 2014, 124, 3430-3430.	1.4	0
104	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. Blood, 2014, 124, 4719-4719.	1.4	0
105	Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques. Blood, 2014, 124, 2978-2978.	1.4	1
106	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. Blood, 2014, 124, 2056-2056.	1.4	0
107	microRNA Aberrations in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 205-207.	0.4	14
108	Genomic Studies Have Identified Multiple Mechanisms of Genetic Changes in WaldenstrÃ¶m Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 202-204.	0.4	8

#	Article	IF	Citations
109	Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia. American Journal of Hematology, 2013, 88, 948-954.	4.1	45
110	Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways. Blood, 2013, 122, 273-273.	1.4	3
111	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. Blood, 2013, 122, 680-680.	1.4	4
112	Myeloma, IMiDs and thrombosis. Hematologie, 2013, 19, 33-40.	0.0	1
113	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. Blood, 2013, 122, 3086-3086.	1.4	2
114	Extramedullary Disease In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 1773-1773.	1.4	0
115	Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo. Blood, 2013, 122, 275-275.	1.4	0
116	Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma. Blood, 2013, 122, 3093-3093.	1.4	0
117	Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia, 2012, 26, 2552-2554.	7.2	1
118	Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia. Clinical Cancer Research, 2012, 18, 6609-6622.	7.0	14
119	Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. Expert Review of Hematology, 2012, 5, 619-629.	2.2	15
120	Prognostic value of PINI index in patients with multiple myeloma. European Journal of Haematology, 2012, 88, 306-313.	2.2	22
121	Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients. Blood, 2012, 120, 3975-3975.	1.4	2
122	In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. Blood, 2012, 120, 440-440.	1.4	4
123	90-Yttrium Ibritumomab Tiuxetan (Zevalin) and BEAM Chemotherapy (Z-BEAM) Vs BEAM for Autologous Stem Cell Transplantation in Lymphoma: Toxicity and Long Term Outcome From a Retrospective Multicentric Study of 123 Patients.. Blood, 2012, 120, 2726-2726.	1.4	0
124	Multiple Myeloma-Derived Bone-Marrow Mesenchymal Stem Cells: Microrna-, Gene Expression-Profiling and Functional Characterization. Blood, 2012, 120, 1837-1837.	1.4	0
125	IgA HevyliteÂ® Test As a Surrogate to Serum Protein Electrophoresis (SPEP) or Nephelometry in the Management of IgA Myeloma. Blood, 2012, 120, 3970-3970.	1.4	1
126	CXCR4 Monoclonal Antibody, BMS-936564 (MDX-1338), Modulates Epithelial to Mesenchymal Transition (EMT) in Multiple Myeloma Cells. Blood, 2012, 120, 4009-4009.	1.4	0

#	Article	IF	Citations
127	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. Blood, 2012, 120, 3944-3944.	1.4	0
128	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. Blood, 2012, 120, 570-570.	1.4	0
129	High-Throughput Genomic Analysis in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 106-108.	0.4	19
130	Novel M-Component Based Biomarkers in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 164-167.	0.4	23
131	Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2667-2667.	1.4	2
132	The EOSÂ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,. Blood, 2011, 118, 3921-3921.	1.4	1
133	A20 Gene Deregulation In Waldenstrom's Macroglobulinemia.. Blood, 2010, 116, 3628-3628.	1.4	0
134	HevyliteÂ®, a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia. Blood, 2010, 116, 5076-5076.	1.4	3
135	SOCS1 and SOCS3 Genes Are Not Methylated In Waldenstrom Macroglobulinemia. Blood, 2010, 116, 2481-2481.	1.4	0